GlassScriptPhysician profile
Laura Harger
NPI 1891003109
$7,037.41
in general payments reported to CMS, 2019-2025
45 companies · $967 in 2025
The $967 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,385 · 2022: $2,006 · 2023: $1,704 · 2024: $976 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,646.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,398.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,115.94 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $586.17 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.02 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $299.64 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $290.22 | 2021-2025 | Jardiance, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $258.85 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $256.50 | 2021-2024 | Belsomra, Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.82 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $198.51 | 2021-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $190.47 | 2021-2025 | |
| Amarin Pharma, INC. | $189.10 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $177.25 | 2021-2022 | |
| Pfizer INC. | $134.06 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $129.13 | 2022-2023 | Austedo Xr, Austedo |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $124.37 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $123.58 | 2022 | |
| Sanofi-Aventis U.S. LLC | $81.15 | 2021-2024 | |
| Genentech USA, INC. | $79.41 | 2021-2022 | |
| Abbott Laboratories | $75.17 | 2021-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $67.90 | 2022-2025 | Intellis Adaptivestim, Venaseal |
| Sunovion Pharmaceuticals INC. | $65.34 | 2022 | |
| Dexcom, INC. | $57.44 | 2024-2025 | Dexcom G6 Transmitter |
| Stryker Corporation | $49.33 | 2025 | Mako |
| Exact Sciences Corporation | $48.57 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $45.90 | 2022 | |
| Vivus LLC | $43.69 | 2022-2023 | Qsymia |
| Currax Pharmaceuticals LLC | $42.29 | 2021-2022 | |
| Beta Bionics, INC. | $31.20 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Arbor Pharmaceuticals, INC. | $30.74 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.45 | 2021-2023 | Livalo |
| Madrigal Pharmaceuticals | $28.52 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $26.62 | 2023 | Gemtesa |
| Almatica Pharma LLC | $26.46 | 2023-2024 | Loreev Xr |
| Ethicon US, LLC | $25.35 | 2021 | |
| Sanofi Pasteur INC. | $24.74 | 2023 | |
| Esperion Therapeutics, INC. | $21.91 | 2021 | |
| Radius Health, INC. | $21.48 | 2023 | Tymlos |
| Seqirus USA INC | $19.17 | 2025 | Fluad, Flucelvax |
| Renalytix Ai, INC. | $17.53 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Recordati_rare_diseases_inc. | $17.39 | 2025 | Isturisa |
| Insulet Corporation | $14.30 | 2025 | Omnipod |
| Ibsa Pharma INC. | $14.08 | 2025 | Licart, Tirosint, Flector |
| Eisai INC. | $13.71 | 2022 | |
| Therapeuticsmd, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Harger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.